Skip to main content
SpringerLink
Log in

The New Ways of Preventing and Treating Diabetes Mellitus

  • Chapter
  • First Online:
Book cover Prevention of Chronic Diseases and Age-Related Disability

Part of the book series: Practical Issues in Geriatrics ((PIG))

Abstract

Strategies in midlife to prevent development of diabetes mellitus, mostly T2D mellitus (T2D), and its negative late sequela for health are of imminent importance for the individual as well as for societies and health systems. Healthy lifestyle and body-weight control in midlife play a crucial role in avoiding or postponing manifestation of T2D since lifestyle interventions appear more sustainable concerning their preventive potential in comparison to different pharmaceutical approaches which—up to now—loose efficacy after stopping and wash out and bear the risk of side-effects. Therefore, for the time being, no drug is licensed for diabetes prevention. Nonetheless, novel medicamentous attempts for diabetes prevention and supporting healthy aging are under scientific investigation.

If T2D is diagnosed, adequate lifestyle modification and modern pharmaceutical strategies are required to safely control hyperglycemia in order to prevent severe acute and chronic complications, especially severe hypoglycemia and premature cardiovascular complications and death. Diabetes prevention has important implications for health policy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

BMI:

Body mass index

CV:

Cardiovascular

CVD:

Cardiovascular disease

CVOT:

Cardiovascular outcome trial

DPP:

Diabetes Prevention Program [14]

DPP-4-I:

Dipeptidyl-peptidase 4 inhibitors

DPPOS:

Diabetes Prevention Program Outcome Study [15]

DPS:

Diabetes Prevention Study [13]

GLP1-RA:

Glucagon-like-peptide 1 receptor agonist

HbA1c:

Glycosylated hemoglobin A1c

HR:

Hazard ratio

IDF:

International Diabetes Federation

sGLT2-I:

Sodium-glucose-transporter 2 inhibitors

SSB:

Sugar-sweetened beverages

T1D:

Diabetes mellitus type 1

T2D:

Diabetes mellitus type 2

References

  1. International Diabetes Federation. IDF Diabetes Atlas 8th Edition. Available at: http://www.diabetesatlas.org/. Accessed 27 Dec 2017

  2. Roeckl S, Brinks R, Baumert J et al (2017) All cause mortality in adults with and without type 2 diabetes: findings from the national health monitoring in Germany. BMJ Open Diab Res Care 5:e000451. https://doi.org/10.1136/bmjdrc-2017-000451

    Article  Google Scholar 

  3. Bierman AS, Tinetti ME (2016) Precision medicine to precision care: managing multimorbidity. Lancet 388:2721–2723

    Article  Google Scholar 

  4. American Diabetes Association (ADA) (2018) Prevention or delay of type 2 diabetes: standards of medical care in diabetes—2018. Diabetes Care 41(Suppl 1):S51–S54. https://doi.org/10.2337/dc18-S005

    Article  Google Scholar 

  5. American Diabetes Association (ADA) (2018) Approaches to glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care 41(Suppl 1):S73–S85. https://doi.org/10.2337/dc18-S008

    Article  Google Scholar 

  6. Feldman AL, Griffin SJ, Al A et al (2017) Impact of weight maintenance and loss on diabetes risk and burden: a population-based study in 33,184 participants. BMC Public Health 17:170. https://doi.org/10.1186/s12889-017-4081-6

    Article  PubMed  PubMed Central  Google Scholar 

  7. The Global BMI Mortality Collaboration (2016) Body-mass index and all-cause mortality: individual-participant-data-meta-analysis of 239 prospective studies in four continents. Lancet 388:776–786

    Article  Google Scholar 

  8. Gao F, Wang J, Shen H et al (2018) Impact of obesity on mortality in patients with diabetes: meta-analysis of 20 studies including 250,016 patients. J Diabetes Investig 9:44–54. https://doi.org/10.1111/jdi.12677

    Article  CAS  PubMed  Google Scholar 

  9. Lee EY, Lee Y-h, Yi S-W, Shin S-A, Yi J-J (2017) BMI and all-cause mortality in normoglycemia, impaired fasting glucose, newly diagnosed diabetes, and prevalent diabetes: a cohort study. Diabetes Care 40:1026–1033

    Article  Google Scholar 

  10. American Diabetes Association (ADA) (2018) Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care 41(Suppl 1):S13–S27. https://doi.org/10.2337/dc18-S002

    Article  Google Scholar 

  11. Barry E, Roberts S, Oke J et al (2017) Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analyis of screening tests and interventions. BMJ 356:i6538. https://doi.org/10.1136/bmj.i6538

    Article  PubMed  Google Scholar 

  12. Lean MEJ, Leslie WS, Barnes AC et al (2018) Primary care-led weight management for remission of T2D (direct): an open label, cluster-randomised trial. Lancet 391(10120):541–551. https://doi.org/10.1016/S0140-6736(17)33102-1

    Article  PubMed  Google Scholar 

  13. Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of T2D mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350

    Article  CAS  Google Scholar 

  14. Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403

    Article  CAS  Google Scholar 

  15. Aroda VR, Knowler WC, Crandall JP et al (2017) For the diabetes prevention program research group. Metformin for diabetes prevention: insights gained from the diabetes prevention program/diabetes prevention program outcomes study. Diabetologia 60:1601–1611

    Article  CAS  Google Scholar 

  16. Le Roux CW, Astrup A, Fujioka K et al (2017) 3 years of liraglutide vs. placebo for T2Drisk reduction and weight management in individuals with prediabetes: a randomized, double-blind trial. Lancet 389:1399–1409

    Article  Google Scholar 

  17. Haw JS, Galaviz KI, Straus AN et al (2017) Long-term sustainability of diabetes prevention approaches. A systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 177:1808–1817. https://doi.org/10.1001/jamainternmed.2017.6040

    Article  PubMed  PubMed Central  Google Scholar 

  18. Canpbell JM, Bellman SM, Stephensen MD et al (2017) Metformin reduces all-cause mortality and diseases independent of its effect on diabetes control: a systematic review and meta-analysis. Ageing Res Rev 40:31–44. https://doi.org/10.1016/j.arr.2017.08.003

    Article  CAS  Google Scholar 

  19. Valencia WM, Palacio A, Tamariz L, Florez H (2017) Metformin and ageing: improving outcomes beyond glycaemic control. Diabetologia 60:1630–1638

    Article  CAS  Google Scholar 

  20. Aroda VR, Edelstein SL, Goldberg RB et al (2016) Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab 101:1754–1761

    Article  Google Scholar 

  21. Ocampo Chaparro JM (2013) Vitamin B12 deficit and development of geriatric syndromes. Colomb Med (Cali) 44:42–45e PMCID: PMC4002007

    Google Scholar 

  22. Brakedal B, Flones I, Reiter SF et al (2017) Glitazone use associated with reduced risk of Parkinson’s disease. Mov Disord 32(11):1594–1599. https://doi.org/10.1002/mds.27128

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Athauda D, Maclagan K, Skene SS et al (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomized, double-blind, plazebo-controlled trial. Lancet 390:1664–1675

    Article  CAS  Google Scholar 

  24. Bae JP, Lage MJ, Mod NDR, Hoogwerf BJ (2016) Obesity and glycemic control in patients with diabetes mellitus: analysis of physician electronic health records in the US from 2009-2011. J Diab Compl 30:212–220

    Article  CAS  Google Scholar 

  25. Gummesson A, Nyman E, Knutsson M, Karpefors M (2017) Effect of weight reduction on hemoglobin A1c in weight loss trials of T2D patients. Diab Obes Metab 19:1295–1305. https://doi.org/10.1111/dom.12971

    Article  CAS  Google Scholar 

  26. Schauer PR, Deepak BL, Kirwan JP et al (2017) Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med 376:641–651

    Article  Google Scholar 

  27. Fougere B, Morley JE (2017) Weight loss is a major cause of frailty (editorial). J Nutr Health Aging 21(9):933–935

    Article  CAS  Google Scholar 

  28. Sinclair AJ, Abdelhafiz A, Dunning T et al (2017) On behalf of the expert working group. An international position statement on the management of frailty in diabetes mellitus: summary of recommendations 2017. J Frailty Aging. Available at: http://www.jfrailtyaging.com/all-issue.html?artcle=609

  29. Morley JE, Anker SD (2017) Myopenia and precision (P4) medicine. J Cachexia Sarcopenia Muscle 8:857. https://doi.org/10.1002/jcsm.12231

    Article  PubMed  PubMed Central  Google Scholar 

  30. Holst C, Becker U, Jorgensen ME et al (2017) Alcohol drinking patterns and risk of diabetes: a cohort study of 70,551 men and women from the general Danish population. Diabetologia 60:1941–1950. https://doi.org/10.1007/s00125-017-4359-3

    Article  PubMed  Google Scholar 

  31. Kondapally R, Seshasai S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841

    Article  Google Scholar 

  32. Schernthaner G, Lehmann R, Prazny M et al (2017) Translating recent results from the cardiovacular outcome trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). Cardiovasc Diabetol 16:137–149. https://doi.org/10.1186/s12933-017-0622-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Currie CJ, Holden SE, Jenkins-Jones S et al (2018) Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival. J Diab Obes Metab 20:821. https://doi.org/10.1111/dom.13155

    Article  CAS  Google Scholar 

  34. Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735–742

    Article  CAS  Google Scholar 

  35. Jones M, Tett S, Peeters GMEE et al (2017) New-onset diabetes after statin exposure in elderly women: the Australian Longitudinal Study on Women’s Health. Drugs Aging 34:203–209. https://doi.org/10.1007/s40266-017-0435-0

    Article  CAS  PubMed  Google Scholar 

  36. Brown RT, Diaz-Ramirez LG, Boscardin WJ et al (2017) Functional impairment and decline in middle age: a cohort study. Ann Intern Med 167:761–768. https://doi.org/10.7326/M17-0496

    Article  PubMed  PubMed Central  Google Scholar 

  37. Sinharay R, Gong J, Barratt B et al (2018) Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cross-over study. Lancet 391:339–349. https://doi.org/10.1016/s0140-6736(17)32643-0

    Article  PubMed  PubMed Central  Google Scholar 

  38. Silver LD, Ng SW, Ryan-Ibarra S, Smith Taillie L et al (2017) Changes in prices, sales, consumer spending, and beverage consumption one year after tax on sugar-sweetened beverages in Berkeley, California, US: a before-and-after study. PLoS Med 14:e1002283. https://doi.org/10.1371/journal.pmed.1002283

    Article  PubMed  PubMed Central  Google Scholar 

  39. Luger M, Lafontan M, Bes-Rastrollo M et al (2017) Sugar-sweetened beverages and weight gain in children and adults: a systematic review from 2013 to 2015 and a comparison with previous studies. Obes Facts 10:674–693. https://doi.org/10.1159/000484566

    Article  Google Scholar 

  40. Kollannoor-Samuel G, Shbl FM, Hawley NL, Perez-Escamilla R (2017) Nutrition label use is associated with lower long-term diabetes risk in US adults. Am J Clin Nutr 105:1079–1085. https://doi.org/10.3945/ajcn.116.145359

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 5th Internal Department with Endocrinology, Rheumatology and Acute Geriatrics, Wilhelminenspital of the City of Vienna, Vienna, Austria

    Peter Fasching

Authors
  1. Peter Fasching
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Fasching .

Editor information

Editors and Affiliations

  1. Geneva University, Geneva, Switzerland

    Jean-Pierre Michel

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Fasching, P. (2019). The New Ways of Preventing and Treating Diabetes Mellitus. In: Michel, JP. (eds) Prevention of Chronic Diseases and Age-Related Disability. Practical Issues in Geriatrics. Springer, Cham. https://doi.org/10.1007/978-3-319-96529-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-96529-1_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-96528-4

  • Online ISBN: 978-3-319-96529-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation